Literature DB >> 10179702

The economic burden of migraine to society.

M D Ferrari1.   

Abstract

The financial burden of migraine on society comprises direct costs, associated with medical care, and indirect costs, caused by absence from work and reduced productivity. Recent studies have revealed that direct costs are generally relatively low in Europe, but are much higher in North America, probably because of increased use of emergency room and specialist consultations for the treatment of migraine. Most individuals who experience migraine headaches take medication (over-the-counter, prescription-only or a combination of both) for their condition; in Europe and North America, most patients who experience migraines have consulted a physician at some time because of their condition. In general, the estimated indirect costs of migraine are substantial and are much higher than estimates of direct costs. On average, work losses related to reduced productivity are higher than those related to work absence. These data demonstrate the importance of the societal impact of migraine and illustrate the need for improved strategies to target migraine treatment.

Entities:  

Mesh:

Year:  1998        PMID: 10179702     DOI: 10.2165/00019053-199813060-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  20 in total

1.  Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.

Authors:  W F Stewart; R B Lipton; D D Celentano; M L Reed
Journal:  JAMA       Date:  1992-01-01       Impact factor: 56.272

2.  Healthcare resource and lost labour costs of migraine headache in the US.

Authors:  J T Osterhaus; D L Gutterman; J R Plachetka
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

3.  Societal perspective on the burden of migraine in The Netherlands.

Authors:  L van Roijen; M L Essink-Bot; M A Koopmanschap; B C Michel; F F Rutten
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

4.  The economic costs of non-insulin-dependent diabetes mellitus.

Authors:  D M Huse; G Oster; A R Killen; M J Lacey; G A Colditz
Journal:  JAMA       Date:  1989-11-17       Impact factor: 56.272

5.  Medication use and disability among migraineurs: a national probability sample survey.

Authors:  D D Celentano; W F Stewart; R B Lipton; M L Reed
Journal:  Headache       Date:  1992-05       Impact factor: 5.887

6.  Prevalence of migraine and other headaches in Hong Kong.

Authors:  T W Wong; K S Wong; T S Yu; R Kay
Journal:  Neuroepidemiology       Date:  1995       Impact factor: 3.282

7.  Impact of migraine in the United States: data from the National Health Interview Survey.

Authors:  P E Stang; J T Osterhaus
Journal:  Headache       Date:  1993-01       Impact factor: 5.887

8.  Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults.

Authors:  N Breslau; G C Davis; P Andreski
Journal:  Psychiatry Res       Date:  1991-04       Impact factor: 3.222

9.  Impact of headache on sickness absence and utilisation of medical services: a Danish population study.

Authors:  B K Rasmussen; R Jensen; J Olesen
Journal:  J Epidemiol Community Health       Date:  1992-08       Impact factor: 3.710

10.  Emergency department resource use by patients with migraine and asthma in a health maintenance organization.

Authors:  K A Kaa; J A Carlson; J T Osterhaus
Journal:  Ann Pharmacother       Date:  1995-03       Impact factor: 3.154

View more
  41 in total

Review 1.  Ibuprofen with or without an antiemetic for acute migraine headaches in adults.

Authors:  Roy Rabbie; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

Authors:  Junhua Yu; Kenneth J Smith; Diana I Brixner
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

4.  Sumatriptan plus naproxen for acute migraine headaches in adults.

Authors:  Simon Law; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2010

5.  Zolmitriptan for acute migraine headaches in adults.

Authors:  Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010

Review 6.  Migraine: multiple processes, complex pathophysiology.

Authors:  Rami Burstein; Rodrigo Noseda; David Borsook
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

Review 7.  Workplace productivity. A review of the impact of migraine and its treatment.

Authors:  P Stang; R Cady; A Batenhorst; L Hoffman
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Eletriptan for acute migraine headaches in adults.

Authors:  Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010

9.  Rizatriptan for acute migraine headaches in adults.

Authors:  Rebecca Ling; Sheena Derry; R Andrew Moore; Henry J McQuay; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2010

10.  Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.

Authors:  André Pradalier; Jean-Paul Auray; Abdelkader El Hasnaoui; Kazem Alzahouri; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lantéri-Minet; Christian Lucas; Guy Chazot; Anne-François Gaudin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.